Arvinas

ARVN Rare disease Lead: Approved 6 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-24

Catalyst timeline

ARV-393 Ph1 interim2H 2026ARV-393 Ph1 interim, 2H 2026, notable
ARV-6723 Ph1 start3Q 2026ARV-6723 Ph1 start, 3Q 2026, routine
ARV-027 polyQ-AR readout3Q 2026ARV-027 polyQ-AR readout, 3Q 2026, routine
ARV-806 KRAS readout2H 2026ARV-806 KRAS readout, 2H 2026, routine
ARV-102 Ph1 start2027ARV-102 Ph1 start, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

VEPPANU

vepdegestrant · ARV-471

Small Molecule Target: estrogen receptor, ER, ESR1

Breast Cancer Approved oral Rigel Pharmaceuticals NCT04072952

Undisclosed indication Preclinical oral NCT07749586

luxdegalutamide

ARV-766

Small Molecule Target: androgen receptor, AR

Metastatic Castration-Resistant Prostate Cancer Phase 3 oral Novartis
Prostate Cancer Phase 1 Novartis

pan-KRAS degrader

Small Molecule Target: KRAS

Undisclosed indication Preclinical

Technology platforms

PROTAC Discovery Engine

Integrated suite of tools and expertise for discovery and optimization of PROTAC targeted protein degraders, including E3KnowledgeBase, ANGLE linker evolution, LEAP library format, PROTACify ML modeling, proteomics capabilities, and PIVOT PK/PD tool. Focus areas: oncology and neurology, including historically undruggable intracellular targets such as transcription factors, scaffolding proteins, and oncoproteins.

PROTAC

PROteolysis TArgeting Chimera protein degrader platform — harnesses the body's natural protein disposal system to selectively degrade disease-causing intracellular proteins, including historically undruggable targets, across oncology and neurology indications.

PROTAC protein degrader platform

PROteolysis TArgeting Chimera (PROTAC) protein degrader platform that harnesses the body's natural protein disposal system to selectively and efficiently degrade disease-causing intracellular proteins, including historically undruggable targets; applied across oncology and neurology indications.

PROTAC · Pfizer

PROteolysis TArgeting Chimera protein degrader platform — harnesses the body's natural protein disposal system (ubiquitin-proteasome system) to selectively degrade disease-causing proteins; applied across oncology and neurology indications

Discontinued (1)

bavdegalutamide — Metastatic Castration-Resistant Prostate Cancer · deprioritized in favor of luxdegalutamide; clinical trials completed Q2 2025

Biotech Distilled coverage (6)

2026-08-04 UPDATE: Arvinas (ARVN) - The Catalyst Window Just Slid a Year Right 🔒 Paid
2026-06-22 UPDATE: Arvinas (ARVN) - The CMO Walks Three Weeks Before the Catalyst Window Opens 🔒 Paid
2026-06-02 UPDATE: Arvinas (ARVN) - The KRAS Asset Gets the Novartis Treatment
2026-05-12 UPDATE: Arvinas (ARVN) - The Partner Lands. The Tape Yawns. 🔒 Paid
2026-05-02 UPDATE: Arvinas (ARVN) - The First PROTAC Crosses the Finish Line 🔒 Paid
2026-04-10 Arvinas (ARVN) - Scientific Deep Dive for Vepdegestrant, Luxdegalutamide, and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.